07/14/26 · 4 min read
Amylyx securities settlement: $6.5M for AMLX investors over the Relyvrio launch
By ClaimBridge Team
If you bought Amylyx Pharmaceuticals (AMLX) stock between November 11, 2022 and November 8, 2023 and held past the November 2023 disclosure, a $6.5 million settlement will pay a pro-rata share of your recognized loss — the notice estimates about $0.16 per share net on average. Claims are due August 31, 2026.
What this settlement is about
Shih v. Amylyx Pharmaceuticals (D. Mass., No. 1:24-cv-12068) alleged that Amylyx misled investors about the commercial trajectory of Relyvrio (AMX0035), its ALS treatment, during the launch. The defendants deny wrongdoing.
Who qualifies and how much
Purchasers of AMLX common stock during the class period who were damaged. Recognized loss is capped at $4.80 per share, shares sold on or before November 8, 2023 recognize nothing, and distributions under $10 aren't made — so the claim is most meaningful for positions of roughly 100+ shares held past the disclosure.
How to file
The claim needs your documented AMLX transaction history from November 2022 through February 2024 (broker confirmations or statements) plus a tax ID. The administrator's online portal takes individual claims directly, and representatives may file with evidence of authority — ClaimBridge readies the trade documentation so your registration takes minutes. The official settlement site is strategicclaims.net/case/amylyx. The deadline is August 31, 2026.
Frequently asked questions
How much does the Amylyx settlement pay?
The notice estimates roughly $0.24 per affected share gross (~$0.16 net) across about 27.1 million shares, pro rata by recognized loss, with a $4.80/share cap and a $10 minimum distribution.
I sold my AMLX before November 8, 2023 — do I recover?
No. Shares sold on or before November 8, 2023 have a recognized loss of $0 under the plan of allocation.
What records do I need?
Broker confirmations or account statements covering your AMLX holdings and every trade from November 11, 2022 through February 6, 2024, plus your SSN or tax ID for the claim's Substitute W-9.